Interferon gamma in autoimmunity: A complicated player on a complex stage

Cytokine

Volumn 74, Issue 1, 2015, Pages 18-26

  Lees, Jason R ^a  

^a Uniformed Services University of the Health Sciences   (United States)

Author keywords

Autoimmunity; Immune pathology; Immune regulation; Inflammation; Interferon gamma

Indexed keywords

GAMMA INTERFERON; REACTIVE OXYGEN METABOLITE; CYTOKINE; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; CYTOKINE PRODUCTION; GROWTH INHIBITION; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC REGULATION; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; IMMUNOLOGY; INFLAMMATION;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; INTERFERON-GAMMA; SIGNAL TRANSDUCTION;

EID: 84930181212     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.10.014     Document Type: Article

References (171)

1. Marsters S.A., Pennica D., Bach E., Schreiber R.D., Ashkenazi A. Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain. Proc Natl Acad Sci USA 1995, 92:5401-5405.
2. Watling D., Carmo C.R., Kerr I.M., Costa-Pereira A.P. Multiple kinases in the interferon-gamma response. Proc Natl Acad Sci USA 2008, 105:6051-6056.
3. Gough D.J., Levy D.E., Johnstone R.W., Clarke C.J. IFN gamma signaling - does it mean JAK-STAT?. Cytokine Growth Factor Rev 2008, 19:383-394.
4. Hu X., Ivashkiv L.B. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 2009, 31:539-550.
5. Kai J.I., Huang W.C., Tsai C.C., Chang W.T., Chen C.L., Lin C.F. Glycogen synthase kinase-3beta indirectly facilitates interferon-gamma-induced nuclear factor-kappaB activation and nitric oxide biosynthesis. J Cell Biochem 2010, 111:1522-1530.
6. Marine J.C., Topham D.J., McKay C., Wang D., Parganas E., Stravopodis D., et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 1999, 98:609-616.
7. Rigamonti L., Ariotti S., Losana G., Gradini R., Russo M.A., Jouanguy E., et al. Surface expression of the IFN-gamma R2 chain is regulated by intracellular trafficking in human T lymphocytes. J Immunol 2000, 164:201-207.
8. Sato T., Selleri C., Young N.S., Maciejewski J.P. Hematopoietic inhibition by interferon-gamma is partially mediated through interferon regulatory factor-1. Blood 1995, 86:3373-3380.
9. Sato T., Selleri C., Young N.S., Maciejewski J.P. Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-gamma due to phosphorylation of Stat1 and Stat3. Blood 1997, 90:4749-4758.
10. Blouin C.M., Lamaze C. Interferon gamma receptor: the beginning of the journey. Front Immunol 2013, 4:267.
11. Novelli F., Bernabei P., Ozmen L., Rigamonti L., Allione A., Pestka S., et al. Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-gamma is correlated with the differential expression of the alpha- and beta-chains of its receptor. J Immunol 1996, 157:1935-1943.
12. Novelli F., D'Elios M.M., Bernabei P., Ozmen L., Rigamonti L., Almerigogna F., et al. Expression and role in apoptosis of the alpha- and beta-chains of the IFN-gamma receptor on human Th1 and Th2 clones. J Immunol 1997, 159:206-213.
13. Novelli F., Giovarelli M., Gentz R., Zucca M., di Pierro F., Garotta G., et al. Modulation of interferon-gamma receptor during human T lymphocyte alloactivation. Eur J Immunol 1993, 23:1226-1231.
14. Valente G., Ozmen L., Novelli F., Geuna M., Palestro G., Forni G., et al. Distribution of interferon-gamma receptor in human tissues. Eur J Immunol 1992, 22:2403-2412.
15. Haring J.S., Corbin G.A., Harty J.T. Dynamic regulation of IFN-gamma signaling in antigen-specific CD8+ T cells responding to infection. J Immunol 2005, 174:6791-6802.
16. Novelli F., Di Pierro F., Francia di Celle P., Bertini S., Affaticati P., Garotta G., et al. Environmental signals influencing expression of the IFN-gamma receptor on human T cells control whether IFN-gamma promotes proliferation or apoptosis. J Immunol 1994, 152:496-504.
17. Aune T.M., Collins P.L., Collier S.P., Henderson M.A., Chang S. Epigenetic activation and silencing of the gene that encodes IFN-gamma. Front Immunol 2013, 4:112.
18. Gomez J.A., Wapinski O.L., Yang Y.W., Bureau J.F., Gopinath S., Monack D.M., et al. The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-gamma locus. Cell 2013, 152:743-754.
19. Novelli F., Giovarelli M., Reber-Liske R., Virgallita G., Garotta G., Forni G. Blockade of physiologically secreted IFN-gamma inhibits human T lymphocyte and natural killer cell activation. J Immunol 1991, 147:1445-1452.
20. Collier S.P., Collins P.L., Williams C.L., Boothby M.R., Aune T.M. Cutting edge: influence of Tmevpg1, a long intergenic noncoding RNA, on the expression of Ifng by Th1 cells. J Immunol 2012, 189:2084-2088.
21. Gresser I., Tovey M.G., Maury C., Chouroulinkov I. Lethality of interferon preparations for newborn mice. Nature 1975, 258:76-78.
22. Marciano B.E., Wesley R., De Carlo E.S., Anderson V.L., Barnhart L.A., Darnell D., et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis: An Off Pub Inf Dis Soc Am 2004, 39:692-699.
23. Gao X.F., Yang Z.W., Li J. Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review. Int J Inf Dis: IJID: Off Pub Int Soc Inf Dis 2011, 15:e594-e600.
24. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Annu Rev Immunol 1997, 15:749-795.
25. Spits H., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., et al. Innate lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol 2013, 13:145-149.
26. Hazenberg M.D., Spits H. Human innate lymphoid cells. Blood 2014, 124:700-709.
27. Bao Y., Liu X., Han C., Xu S., Xie B., Zhang Q., et al. Identification of IFN-gamma-producing innate B cells. Cell Res 2014, 24:161-176.
28. Schindler H., Lutz M.B., Rollinghoff M., Bogdan C. The production of IFN-gamma by IL-12/IL-18-activated macrophages requires STAT4 signaling and is inhibited by IL-4. J Immunol 2001, 166:3075-3082.
29. Munder M., Mallo M., Eichmann K., Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 1998, 187:2103-2108.
30. Schleicher U., Hesse A., Bogdan C. Minute numbers of contaminant CD8+ T cells or CD11b+CD11c+ NK cells are the source of IFN-gamma in IL-12/IL-18-stimulated mouse macrophage populations. Blood 2005, 105:1319-1328.
31. Darwich L., Coma G., Pena R., Bellido R., Blanco E.J., Este J.A., et al. Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology 2009, 126:386-393.
32. Vremec D., O'Keeffe M., Hochrein H., Fuchsberger M., Caminschi I., Lahoud M., et al. Production of interferons by dendritic cells, plasmacytoid cells, natural killer cells, and interferon-producing killer dendritic cells. Blood 2007, 109:1165-1173.
33. Sturge C.R., Benson A., Raetz M., Wilhelm C.L., Mirpuri J., Vitetta E.S., et al. TLR-independent neutrophil-derived IFN-gamma is important for host resistance to intracellular pathogens. Proc Natl Acad Sci USA 2013, 110:10711-10716.
34. Zaidi M.R., Davis S., Noonan F.P., Graff-Cherry C., Hawley T.S., Walker R.L., et al. Interferon-gamma links ultraviolet radiation to melanomagenesis in mice. Nature 2011, 469:548-553.
35. Rusinova I., Forster S., Yu S., Kannan A., Masse M., Cumming H., et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res 2013, 41:D1040-D1046.
36. Villella A., Picard C., Jouanguy E., Dupuis S., Popko S., Abughali N., et al. Recurrent Mycobacterium avium osteomyelitis associated with a novel dominant interferon gamma receptor mutation. Pediatrics 2001, 107:E47.
37. Dupuis S., Doffinger R., Picard C., Fieschi C., Altare F., Jouanguy E., et al. Human interferon-gamma-mediated immunity is a genetically controlled continuous trait that determines the outcome of mycobacterial invasion. Immunol Rev 2000, 178:129-137.
38. Smith N.L., Denning D.W. Clinical implications of interferon gamma genetic and epigenetic variants. Immunology 2014.
39. Bax H.I., Freeman A.F., Ding L., Hsu A.P., Marciano B., Kristosturyan E., et al. Interferon alpha treatment of patients with impaired interferon gamma signaling. J Clin Immunol 2013, 33:991-1001.
40. Karupiah G., Xie Q.W., Buller R.M., Nathan C., Duarte C., MacMicking J.D. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 1993, 261:1445-1448.
41. Gao P.Q., Sims S.H., Chang D.C., Deisseroth A.B. Interferon-gamma priming effects in the activation and deactivation of ISGF3 in K562 cells. J Biol Chem 1993, 268:12380-12387.
42. Weihua X., Kolla V., Kalvakolanu D.V. Interferon gamma-induced transcription of the murine ISGF3gamma (p48) gene is mediated by novel factors. Proc Natl Acad Sci USA 1997, 94:103-108.
43. Ronnblom L., Eloranta M.L. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 2013, 25:248-253.
44. Narumi S., Tebo J.M., Finke J.H., Hamilton T.A. IFN-gamma and IL-2 cooperatively activate NF kappa B in murine peritoneal macrophages. J Immunol 1992, 149:529-534.
45. Yasumoto K., Okamoto S., Mukaida N., Murakami S., Mai M., Matsushima K. Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-kB-like binding sites of the interleukin 8 gene. J Biol Chem 1992, 267:22506-22511.
46. Hu X., Chung A.Y., Wu I., Foldi J., Chen J., Ji J.D., et al. Integrated regulation of Toll-like receptor responses by Notch and interferon-gamma pathways. Immunity 2008, 29:691-703.
47. Wilke C.M., Wei S., Wang L., Kryczek I., Kao J., Zou W. Dual biological effects of the cytokines interleukin-10 and interferon-gamma. Cancer Immunol Immun: CII 2011, 60:1529-1541.
48. Couper K.N., Blount D.G., Riley E.M. IL-10: the master regulator of immunity to infection. J Immunol 2008, 180:5771-5777.
49. Chin Y.E., Kitagawa M., Su W.C., You Z.H., Iwamoto Y., Fu X.Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996, 272:719-722.
50. Ramana C.V., Grammatikakis N., Chernov M., Nguyen H., Goh K.C., Williams B.R., et al. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J 2000, 19:263-272.
51. Sloand E.M., Young N.S., Sato T., Kim S., Maciejewski J.P. Inhibition of interleukin-1beta-converting enzyme in human hematopoietic progenitor cells results in blockade of cytokine-mediated apoptosis and expansion of their proliferative potential. Exp Hematol 1998, 26:1093-1099.
52. Watanabe Y., Suzuki O., Haruyama T., Akaike T. Interferon-gamma induces reactive oxygen species and endoplasmic reticulum stress at the hepatic apoptosis. J Cell Biochem 2003, 89:244-253.
53. Lin W., Harding H.P., Ron D., Popko B. Endoplasmic reticulum stress modulates the response of myelinating oligodendrocytes to the immune cytokine interferon-gamma. J Cell Biol 2005, 169:603-612.
54. Pirot P., Eizirik D.L., Cardozo A.K. Interferon-gamma potentiates endoplasmic reticulum stress-induced death by reducing pancreatic beta cell defence mechanisms. Diabetologia 2006, 49:1229-1236.
55. Rao R.V., Ellerby H.M., Bredesen D.E. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 2004, 11:372-380.
56. Seifert U., Bialy L.P., Ebstein F., Bech-Otschir D., Voigt A., Schroter F., et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 2010, 142:613-624.
57. Lin W., Bailey S.L., Ho H., Harding H.P., Ron D., Miller S.D., et al. The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage. J Clin Investig 2007, 117:448-456.
58. Matsuzawa T., Kim B.H., Shenoy A.R., Kamitani S., Miyake M., Macmicking J.D. IFN-gamma elicits macrophage autophagy via the p38 MAPK signaling pathway. J Immunol 2012, 189:813-818.
59. Briesemeister D., Sommermeyer D., Loddenkemper C., Loew R., Uckert W., Blankenstein T., et al. Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis. Int J Cancer J Int du Cancer 2011, 128:371-378.
60. Narumi S., Finke J.H., Hamilton T.A. Interferon gamma and interleukin 2 synergize to induce selective monokine expression in murine peritoneal macrophages. J Biol Chem 1990, 265:7036-7041.
61. Issekutz A.C., Issekutz T.B. Quantitation and kinetics of blood monocyte migration to acute inflammatory reactions, and IL-1 alpha, tumor necrosis factor-alpha, and IFN-gamma. J Immunol 1993, 151:2105-2115.
62. Rauch I., Muller M., Decker T. The regulation of inflammation by interferons and their STATs. JAK-STAT 2013, 2:e23820.
63. Zella D., Barabitskaja O., Burns J.M., Romerio F., Dunn D.E., Revello M.G., et al. Interferon-gamma increases expression of chemokine receptors CCR1, CCR3, and CCR5, but not CXCR4 in monocytoid U937 cells. Blood 1998, 91:4444-4450.
64. Frausto-Del-Rio D., Soto-Cruz I., Garay-Canales C., Ambriz X., Soldevila G., Carretero-Ortega J., et al. Interferon gamma induces actin polymerization, Rac1 activation and down regulates phagocytosis in human monocytic cells. Cytokine 2012, 57:158-168.
65. Hu Y., Hu X., Boumsell L., Ivashkiv L.B. IFN-gamma and STAT1 arrest monocyte migration and modulate RAC/CDC42 pathways. J Immunol 2008, 180:8057-8065.
66. Page C.E., Smale S., Carty S.M., Amos N., Lauder S.N., Goodfellow R.M., et al. Interferon-gamma inhibits interleukin-1beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthrit Res Ther 2010, 12:R49.
67. Nathan C.F., Murray H.W., Wiebe M.E., Rubin B.Y. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983, 158:670-689.
68. Nathan C.F., Prendergast T.J., Wiebe M.E., Stanley E.R., Platzer E., Remold H.G., et al. Activation of human macrophages. Comparison of other cytokines with interferon-gamma. J Exp Med 1984, 160:600-605.
69. Mackaness G.B. The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med 1969, 129:973-992.
70. Nussler A.K., Billiar T.R., Liu Z.Z., Morris S.M. Coinduction of nitric oxide synthase and argininosuccinate synthetase in a murine macrophage cell line. Implications for regulation of nitric oxide production. J Biol Chem 1994, 269:1257-1261.
71. Gupta J.W., Kubin M., Hartman L., Cassatella M., Trinchieri G. Induction of expression of genes encoding components of the respiratory burst oxidase during differentiation of human myeloid cell lines induced by tumor necrosis factor and gamma-interferon. Cancer Res 1992, 52:2530-2537.
72. Goldszmid R.S., Caspar P., Rivollier A., White S., Dzutsev A., Hieny S., et al. NK cell-derived interferon-gamma orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection. Immunity 2012, 36:1047-1059.
73. Steimle V., Siegrist C.A., Mottet A., Lisowska-Grospierre B., Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994, 265:106-109.
74. Sheng K.C., Day S., Wright M.D., Stojanovska L., Apostolopoulos V. Enhanced dendritic cell-mediated antigen-specific CD4+ T cell responses: IFN-gamma aids TLR stimulation. J Drug Del 2013, 2013:516749.
75. Wallach D., Fellous M., Revel M. Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature 1982, 299:833-836.
76. Heink S., Ludwig D., Kloetzel P.M., Kruger E. IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci USA 2005, 102:9241-9246.
77. Strehl B., Seifert U., Kruger E., Heink S., Kuckelkorn U., Kloetzel P.M. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev 2005, 207:19-30.
78. Kloetzel P.M. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2001, 2:179-187.
79. Basler M., Kirk C.J., Groettrup M. The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol 2013, 25:74-80.
80. Barois N., Forquet F., Davoust J. Actin microfilaments control the MHC class II antigen presentation pathway in B cells. J Cell Sci 1998, 111(Pt 13):1791-1800.
81. Fierz W., Endler B., Reske K., Wekerle H., Fontana A. Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol 1985, 134:3785-3793.
82. Collins T., Korman A.J., Wake C.T., Boss J.M., Kappes D.J., Fiers W., et al. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA 1984, 81:4917-4921.
83. Pober J.S., Collins T., Gimbrone M.A., Cotran R.S., Gitlin J.D., Fiers W., et al. Lymphocytes recognize human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune interferon. Nature 1983, 305:726-729.
84. Takikawa O. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism. Biochem Biophys Res Commun 2005, 338:12-19.
85. Muller A.J., Sharma M.D., Chandler P.R., Duhadaway J.B., Everhart M.E., Johnson B.A., et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci USA 2008, 105:17073-17078.
86. Raber P., Ochoa A.C., Rodriguez P.C. Metabolism of l-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 2012, 41:614-634.
87. Modolell M., Corraliza I.M., Link F., Soler G., Eichmann K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol 1995, 25:1101-1104.
88. Munder M., Eichmann K., Moran J.M., Centeno F., Soler G., Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 1999, 163:3771-3777.
89. Liscovsky M.V., Ranocchia R.P., Gorlino C.V., Alignani D.O., Moron G., Maletto B.A., et al. Interferon-gamma priming is involved in the activation of arginase by oligodeoxinucleotides containing CpG motifs in murine macrophages. Immunology 2009, 128:e159-e169.
90. Lazarevic V., Glimcher L.H., Lord G.M. T-bet: a bridge between innate and adaptive immunity. Nat Rev Immunol 2013, 13:777-789.
91. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
92. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
93. Cruz A., Khader S.A., Torrado E., Fraga A., Pearl J.E., Pedrosa J., et al. Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J Immunol 2006, 177:1416-1420.
94. Kebir H., Ifergan I., Alvarez J.I., Bernard M., Poirier J., Arbour N., et al. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 2009, 66:390-402.
95. Doodes P.D., Cao Y., Hamel K.M., Wang Y., Rodeghero R.L., Mikecz K., et al. IFN-gamma regulates the requirement for IL-17 in proteoglycan-induced arthritis. J Immunol 2010, 184:1552-1559.
96. Boniface K., Blumenschein W.M., Brovont-Porth K., McGeachy M.J., Basham B., Desai B., et al. Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage. J Immunol 2010, 185:679-687.
97. Kryczek I., Bruce A.T., Gudjonsson J.E., Johnston A., Aphale A., Vatan L., et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008, 181:4733-4741.
98. Ouaked N., Mantel P.Y., Bassin C., Burgler S., Siegmund K., Akdis C.A., et al. Regulation of the foxp3 gene by the Th1 cytokines: the role of IL-27-induced STAT1. J Immunol 2009, 182:1041-1049.
99. Wang Z., Hong J., Sun W., Xu G., Li N., Chen X., et al. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Investig 2006, 116:2434-2441.
100. Wood K.J., Sawitzki B. Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol 2006, 27:183-187.
101. Koch M.A., Tucker-Heard G., Perdue N.R., Killebrew J.R., Urdahl K.B., Campbell D.J. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009, 10:595-602.
102. Yoshimoto T., Nagai N., Ohkusu K., Ueda H., Okamura H., Nakanishi K. LPS-stimulated SJL macrophages produce IL-12 and IL-18 that inhibit IgE production in vitro by induction of IFN-gamma production from CD3intIL-2R beta+ T cells. J Immunol 1998, 161:1483-1492.
103. Yoshimoto T., Okamura H., Tagawa Y.I., Iwakura Y., Nakanishi K. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. Proc Natl Acad Sci USA 1997, 94:3948-3953.
104. Snapper C.M., Paul W.E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987, 236:944-947.
105. Landolfo S., Gariglio M., Gribaudo G., Jemma C., Giovarelli M., Cavallo G. Interferon-gamma is not an antiviral, but a growth-promoting factor for T lymphocytes. Eur J Immunol 1988, 18:503-509.
106. Ossina N.K., Cannas A., Powers V.C., Fitzpatrick P.A., Knight J.D., Gilbert J.R., et al. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997, 272:16351-16357.
107. Selleri C., Maciejewski J.P., Sato T., Young N.S. Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood 1996, 87:4149-4157.
108. Liu Y., Janeway C.A. Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J Exp Med 1990, 172:1735-1739.
109. Mond J.J., Finkelman F.D., Sarma C., Ohara J., Serrate S. Recombinant interferon-gamma inhibits the B cell proliferative response stimulated by soluble but not by Sepharose-bound anti-immunoglobulin antibody. J Immunol 1985, 135:2513-2517.
110. Francois D.T., Katona I.M., June C.H., Wahl L.M., Mond J.J. Examination of the inhibitory and stimulatory effects of IFN-alpha, -beta, and -gamma on human B-cell proliferation induced by various B-cell mitogens. Clin Immunol Immunopathol 1988, 48:297-306.
111. Boyd A.W., Tedder T.F., Griffin J.D., Freedman A.S., Fisher D.C., Daley J., et al. Preexposure of resting B cells to interferon-gamma enhances their proliferative response to subsequent activation signals. Cell Immunol 1987, 106:355-365.
112. Sarvetnick N., Shizuru J., Liggitt D., Martin L., McIntyre B., Gregory A., et al. Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature 1990, 346:844-847.
113. Gu D., Wogensen L., Calcutt N.A., Xia C., Zhu S., Merlie J.P., et al. Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction. J Exp Med 1995, 181:547-557.
114. Carroll J.M., Crompton T., Seery J.P., Watt F.M. Transgenic mice expressing IFN-gamma in the epidermis have eczema, hair hypopigmentation, and hair loss. J Invest Dermatol 1997, 108:412-422.
115. Seery J.P., Carroll J.M., Cattell V., Watt F.M. Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis. J Exp Med 1997, 186:1451-1459.
116. Suscovich T.J., Perdue N.R., Campbell D.J. Type-1 immunity drives early lethality in scurfy mice. Eur J Immunol 2012, 42:2305-2310.
117. Hirsch R.L., Panitch H.S., Johnson K.P. Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro. J Clin Immunol 1985, 5:386-389.
118. Benvenuto R., Paroli M., Buttinelli C., Franco A., Barnaba V., Fieschi C., et al. Tumor necrosis factor-alpha and interferon-gamma synthesis by cerebrospinal fluid-derived T cell clones in multiple sclerosis. Ann N Y Acad Sci 1992, 650:341-346.
119. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002, 8:500-508.
120. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995, 37:424-435.
121. Simpson J.E., Newcombe J., Cuzner M.L., Woodroofe M.N. Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2000, 26:133-142.
122. Panitch H.S., Hirsch R.L., Schindler J., Johnson K.P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987, 37:1097-1102.
123. Skurkovich S., Boiko A., Beliaeva I., Buglak A., Alekseeva T., Smirnova N., et al. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Multiple Sclerosis 2001, 7:277-284.
124. Corbin J.G., Kelly D., Rath E.M., Baerwald K.D., Suzuki K., Popko B. Targeted CNS expression of interferon-gamma in transgenic mice leads to hypomyelination, reactive gliosis, and abnormal cerebellar development. Mol Cell Neurosci 1996, 7:354-370.
125. Lee E., Chanamara S., Pleasure D., Soulika A.M. IFN-gamma signaling in the central nervous system controls the course of experimental autoimmune encephalomyelitis independently of the localization and composition of inflammatory foci. J Neuroinflammat 2012, 9:7.
126. Lublin F.D., Knobler R.L., Kalman B., Goldhaber M., Marini J., Perrault M., et al. Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity 1993, 16:267-274.
127. Lees J.R., Golumbek P.T., Sim J., Dorsey D., Russell J.H. Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J Exp Med 2008, 205:2633-2642.
128. Stromnes I.M., Cerretti L.M., Liggitt D., Harris R.A., Goverman J.M. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008, 14:337-342.
129. Wensky A.K., Furtado G.C., Marcondes M.C., Chen S., Manfra D., Lira S.A., et al. IFN-gamma determines distinct clinical outcomes in autoimmune encephalomyelitis. J Immunol 2005, 174:1416-1423.
130. Krakowski M., Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996, 26:1641-1646.
131. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009, 9:393-407.
132. Gao X., Gillig T.A., Ye P., D'Ercole A.J., Matsushima G.K., Popko B. Interferon-gamma protects against cuprizone-induced demyelination. Mol Cell Neurosci 2000, 16:338-349.
133. Rodriguez M., Pavelko K., Coffman R.L. Gamma interferon is critical for resistance to Theiler's virus-induced demyelination. J Virol 1995, 69:7286-7290.
134. Li X., Lees J.R. Pre-existing central nervous system lesions negate cytokine requirements for regional experimental autoimmune encephalomyelitis development. Immunology 2013, 138:208-215.
135. Dandekar A.A., Anghelina D., Perlman S. Bystander CD8 T-cell-mediated demyelination is interferon-gamma-dependent in a coronavirus model of multiple sclerosis. Am J Pathol 2004, 164:363-369.
136. Keogh B., Atkins G.J., Mills K.H., Sheahan B.J. Role of interferon-gamma and nitric oxide in the neuropathogenesis of avirulent Semliki Forest virus infection. Neuropathol Appl Neurobiol 2003, 29:553-562.
137. Kreutzfeldt M., Bergthaler A., Fernandez M., Bruck W., Steinbach K., Vorm M., et al. Neuroprotective intervention by interferon-gamma blockade prevents CD8+ T cell-mediated dendrite and synapse loss. J Exp Med 2013, 210:2087-2103.
138. Basler M., Mundt S., Muchamuel T., Moll C., Jiang J., Groettrup M., et al. Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med 2014, 6:226-238.
139. Li L., Walker T.L., Zhang Y., Mackay E.W., Bartlett P.F. Endogenous interferon gamma directly regulates neural precursors in the non-inflammatory brain. J Neurosci: Off J Soc Neurosci 2010, 30:9038-9050.
140. Tanner D.C., Cherry J.D., Mayer-Proschel M. Oligodendrocyte progenitors reversibly exit the cell cycle and give rise to astrocytes in response to interferon-gamma. J Neurosci: Off J Soc Neurosci 2011, 31:6235-6246.
141. Lin W., Lin Y. Interferon-gamma inhibits central nervous system myelination through both STAT1-dependent and STAT1-independent pathways. J Neurosci Res 2010, 88:2569-2577.
142. Lin W., Kemper A., Dupree J.L., Harding H.P., Ron D., Popko B. Interferon-gamma inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. Brain: A J Neurol 2006, 129:1306-1318.
143. Sosa R.A., Forsthuber T.G. The critical role of antigen-presentation-induced cytokine crosstalk in the central nervous system in multiple sclerosis and experimental autoimmune encephalomyelitis. J Interferon Cytok Res: Off J Int Soc Interferon Cytokine Res 2011, 31:753-768.
144. Kim E.Y., Moudgil K.D. Regulation of autoimmune inflammation by pro-inflammatory cytokines. Immunol Lett 2008, 120:1-5.
145. Mauritz N.J., Holmdahl R., Jonsson R., Van der Meide P.H., Scheynius A., Klareskog L. Treatment with gamma-interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum 1988, 31:1297-1304.
146. Nakajima H., Takamori H., Hiyama Y., Tsukada W. The effect of treatment with interferon-gamma on type II collagen-induced arthritis. Clin Exp Immunol 1990, 81:441-445.
147. Vermeire K., Heremans H., Vandeputte M., Huang S., Billiau A., Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997, 158:5507-5513.
148. Manoury-Schwartz B., Chiocchia G., Bessis N., Abehsira-Amar O., Batteux F., Muller S., et al. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol 1997, 158:5501-5506.
149. Matthys P., Vermeire K., Mitera T., Heremans H., Huang S., Schols D., et al. Enhanced autoimmune arthritis in IFN-gamma receptor-deficient mice is conditioned by mycobacteria in Freund's adjuvant and by increased expansion of Mac-1+ myeloid cells. J Immunol 1999, 163:3503-3510.
150. Chu C.Q., Swart D., Alcorn D., Tocker J., Elkon K.B. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum 2007, 56:1145-1151.
151. Satpute S.R., Rajaiah R., Polumuri S.K., Moudgil K.D. Tolerization with Hsp65 induces protection against adjuvant-induced arthritis by modulating the antigen-directed interferon-gamma, interleukin-17, and antibody responses. Arthritis Rheum 2009, 60:103-113.
152. Brasted M., Spargo L.D., Mayrhofer G., Cleland L.G. Blockade of IFN-gamma does not affect the arthritogenicity of T cells generated during the induction of adjuvant arthritis but exacerbates the polyarthritis produced by adoptive transfer of arthritogenic effector cells. Immunol Cell Biol 2005, 83:189-195.
153. Katz J.D., Benoist C., Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995, 268:1185-1188.
154. Campbell I.L., Kay T.W., Oxbrow L., Harrison L.C. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Investig 1991, 87:739-742.
155. Debray-Sachs M., Carnaud C., Boitard C., Cohen H., Gresser I., Bedossa P., et al. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J Autoimmun 1991, 4:237-248.
156. Thomas H.E., Parker J.L., Schreiber R.D., Kay T.W. IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes. J Clin Investig 1998, 102:1249-1257.
157. Serreze D.V., Post C.M., Chapman H.D., Johnson E.A., Lu B., Rothman P.B. Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes 2000, 49:2007-2011.
158. Kim S.K., Tarbell K.V., Sanna M., Vadeboncoeur M., Warganich T., Lee M., et al. Prevention of type I diabetes transfer by glutamic acid decarboxylase 65 peptide 206-220-specific T cells. Proc Natl Acad Sci USA 2004, 101:14204-14209.
159. Jacob C.O., van der Meide P.H., McDevitt H.O. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987, 166:798-803.
160. Balomenos D., Rumold R., Theofilopoulos A.N. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Investig 1998, 101:364-371.
161. Richards H.B., Satoh M., Jennette J.C., Croker B.P., Yoshida H., Reeves W.H. Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int 2001, 60:2173-2180.
162. Kono D.H., Balomenos D., Pearson D.L., Park M.S., Hildebrandt B., Hultman P., et al. The prototypic Th2 autoimmunity induced by mercury is dependent on IFN-gamma and not Th1/Th2 imbalance. J Immunol 1998, 161:234-240.
163. Hu X., Herrero C., Li W.P., Antoniv T.T., Falck-Pedersen E., Koch A.E., et al. Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation. Nat Immunol 2002, 3:859-866.
164. Fox R.I. Sjogren's syndrome. Lancet 2005, 366:321-331.
165. Hjelmervik T.O., Petersen K., Jonassen I., Jonsson R., Bolstad A.I. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 2005, 52:1534-1544.
166. Kimoto O., Sawada J., Shimoyama K., Suzuki D., Nakamura S., Hayashi H., et al. Activation of the interferon pathway in peripheral blood of patients with Sjogren's syndrome. J Rheumatol 2011, 38:310-316.
167. Pelegrino F.S., Volpe E.A., Gandhi N.B., Li D.Q., Pflugfelder S.C., de Paiva C.S. Deletion of interferon-gamma delays onset and severity of dacryoadenitis in CD25KO mice. Arthritis Res Ther 2012, 14:R234.
168. Yin H., Vosters J.L., Roescher N., D'Souza A., Kurien B.T., Tak P.P., et al. Location of immunization and interferon-gamma are central to induction of salivary gland dysfunction in Ro60 peptide immunized model of Sjogren's syndrome. PLoS ONE 2011, 6:e18003.
169. Cha S., Brayer J., Gao J., Brown V., Killedar S., Yasunari U., et al. A dual role for interferon-gamma in the pathogenesis of Sjogren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand J Immunol 2004, 60:552-565.
170. Gao J., Killedar S., Cornelius J.G., Nguyen C., Cha S., Peck A.B. Sjogren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease. J Autoimmun 2006, 26:90-103.
171. Burman A.C., Banovic T., Kuns R.D., Clouston A.D., Stanley A.C., Morris E.S., et al. IFN gamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood 2007, 110:1064-1072.